NASDAQ:XLRN
Delisted
Acceleron Pharma Inc. Stock News
$178.75
+0 (+0%)
At Close: May 27, 2022
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
05:26pm, Monday, 01'st Mar 2021
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q4 2020 Results - Earnings Call Transcript
09:05pm, Thursday, 25'th Feb 2021
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q4 2020 Results - Earnings Call Transcript
Recap: Acceleron Pharma Q4 Earnings
05:00pm, Thursday, 25'th Feb 2021
Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), which mis
Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
07:10am, Thursday, 04'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
5 Biotech Stocks That More Than Doubled This Year
09:47am, Monday, 21'st Dec 2020
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
12:47pm, Friday, 18'th Dec 2020
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popu
Acceleron's (XLRN) PAH Candidate Gets Orphan Designation in EU
10:32am, Tuesday, 15'th Dec 2020
Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.
Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH)
07:00am, Monday, 14'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
Acceleron (XLRN) Up 8.6% Since Last Earnings Report: Can It Continue?
11:32am, Saturday, 05'th Dec 2020
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA
06:03pm, Wednesday, 02'nd Dec 2020
The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.
Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis
07:00am, Tuesday, 01'st Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
Top Healthcare Stocks for December 2020
01:03pm, Thursday, 19'th Nov 2020
These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics t
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript
09:05am, Sunday, 08'th Nov 2020
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript
Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript
07:22pm, Thursday, 05'th Nov 2020
Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript
